75N95022F00003↗

Name: 75N95022F00003: Office-Based Methadone VS Buprenorphine to Address Retention in Medication for Opioid Use Disorder (Moud)-A Pragmatic Hybrid Effectiveness/Implementation Trial (Ctn-013). 09/28/2022 - 08/04/2025. DSC6. 75N95022F00003 (To3).
Creator: SpendQuery

OFFICE-BASED METHADONE VS BUPRENORPHINE TO ADDRESS RETENTION IN MEDICATION FOR OPIOID USE DISORDER (MOUD)-A PRAGMATIC HYBRID EFFECTIVENESS/IMPLEMENTATION TRIAL (CTN-013). 09/28/2022 - 08/04/2025. DSC6. 75N95022F00003 (TO3).

Delivery Order · National Institutes of Health · to The Emmes Company, LLC (UEI NBQCBJ6FXBU4) · data as of 2026-09-30

Obligated to date$834.7K2 actions

Current value$1.86Mwith options exercised

Period2022-09-28 → 2027-01-31current end date

Up for re-bid: ends 2027-01-31. Recompete brief → · CTN Data, Statistics, and Clinical Trial Support Center (DSC7) ↗

What it is

Product or service: Health R&D Services; Health Care Services; Basic Research (PSC AN11)
Industry: Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) (NAICS 541715)
Contracting office: National Institutes of Health Nida (75N950)
Competition: Full and open competition
Pricing: Cost plus fixed fee
How it was bought: Single-award IDIQ · under 75N95022D00017
Solicitation: 75N95022F00003
Where the work is: Montgomery, MD · district MD-08
Topics: opioids

Obligations by fiscal year

FY2024$834.7K

FY2025$0

SpendQuery holds FY2023 on; earlier years are on USAspending.gov.

Subcontractors: where the money went next

No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.

Every action

2 actions since 2024-08-16. Each is a modification or amendment with the money it added or took back.

Date	Modification	Kind	Amount	What the agency wrote
2025-07-30	P00002	Supplemental agreement (work within scope)	$0	OFFICE-BASED METHADONE VS BUPRENORPHINE TO ADDRESS RETENTION IN MEDICATION FOR OPIOID USE DISORDER (MOUD)-A PRAGMATIC HYBRID EFFECTIVENESS/IMPLEMENTATION TRIAL (CTN-013). 09/28/2022 - 01/31/2027. DSC6. 75N95022F00003 (TO3).
2024-08-16	P00001	Option exercised	$834.7K	OFFICE-BASED METHADONE VS BUPRENORPHINE TO ADDRESS RETENTION IN MEDICATION FOR OPIOID USE DISORDER (MOUD)-A PRAGMATIC HYBRID EFFECTIVENESS/IMPLEMENTATION TRIAL (CTN-013). 09/28/2022 - 08/04/2025. DSC6. 75N95022F00003 (TO3).

Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-09-30). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗

Putting the award page together from the records…